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Abstract
Background: Non alcoholic fatty liver disease is an independent risk factor for coronary artery disease. But its effect
on acute coronary syndrome is not clear. We performed this study to identify the prevalence of NAFLD in patients
with ACS admitted to a tertiary care center in Sri Lanka. We also described the association of NAFLD with the
severity of ACS predicted by the GRACE score.
Methods: We performed a descriptive study including all consecutive patients with non-fatal ACS admitted to
Colombo South Teaching Hospital from 01/02/2014 to 30/04/2014. Patients with excessive alcohol consumption,
established cirrhosis and patients with identified risk factors for liver disease were excluded from the study. All
patients underwent ultrasound scan of liver.
Results: There were 120 participants, 75 (62.5 %) males and 45 (37.5 %) females with acute coronary syndrome.
Average age was 61.28 ± 11.83 years. NAFLD was seen in 56 (46.7 %) patients with ACS. Patients with NAFLD had
a higher GRACE score than patients without NAFLD (120.2 ± 26.9 Vs 92.3 ± 24.2, p < 0.001). Increased age and
presence of NAFLD conferred a higher mortality risk from ACS as predicted by GRACE score. Patients with NAFLD
had a higher predicted mortality during in-ward stay (adjusted OR 31.3, CI 2.2–439.8, p = 0.011) and at 6 months
after discharge (adjusted OR 15.59, CI 1.6–130.6, p = 0.011).
Conclusions: Patients with NAFLD have a higher predicted mortality from acute coronary syndrome and thus
require aggressive treatment of CAD. It is important to consider this novel risk factor when risk stratifying patients
with ACS.
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Background
Non alcoholic fatty liver disease (NAFLD) is the hepatic
manifestation of metabolic syndrome [1, 2]. It could pro-
gress to more aggressive non alcoholic steatohepatitis,
cirrhosis and hepatocellular carcinoma [3]. Macrovesicu-
lar steatosis is the characteristic histological finding. The
prevalence of NAFLD has doubled over the last 20 years
becoming the number one cause of liver disease in the
western countries [4]. It is an emerging problem in the
South Asian countries despite having lower body mass
index. Sri Lanka is facing this growing epidemic of
NAFLD and a recent population based study reported a
prevalence of 32.6 % in an urban predominantly seden-
tary population [5].
Insulin resistance, dyslipidaemia and obesity coexist
with NAFLD and these factors predispose to atheroscler-
osis. Longitudinal studies have shown that cardiovascu-
lar disease is one of the important causes of morbidity
and mortality in patients with NAFLD. However, emer-
ging evidence suggest that the risk of coronary artery
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disease in NAFLD is independent of other metabolic risk
factors. These patients have increased carotid artery
intimal thickness, lower endothelial flow mediated vaso-
dilatation, increased coronary calcium score and surro-
gate markers of early atherosclerosis [6, 7]. The exact
mechanism is still unclear, but studies postulate that in-
crease activity of inflammatory mediators [8–10], re-
duced endothelial function, reduced adiponectin levels
[11], reduced collateral circulation [12], reduced vascular
repair capacity [13] and atherogenic lipoprotein profile
contribute to coronary artery disease in these patients.
There is evidence that presence of NAFLD causes
more severe coronary artery disease. Studies have evalu-
ated the coronary plaque burden by angiography or
multi slice CT. Patients with NAFLD are known to have
more complex coronary artery disease in angiography
[14]. But the effect on clinical outcome and mortality is
not known. Furthermore, the impact of NAFLD on acute
coronary syndrome (ACS) is not clear. Presence of such
an association would necessitate the need to screen and
manage coronary artery disease aggressively in patients
with NAFLD. Therefore we performed this study to
compare the predicted mortality and the clinical severity
of acute coronary syndrome in patients both with and
without NAFLD.
We investigated the prevalence of NAFLD in patients
with ACS admitted to a tertiary care center in Sri Lanka,
the association of NAFLD with ACS and its effect on
the severity of ACS as predicted by the GRACE score.
Methods
This was a descriptive study performed in the University
medical unit at Colombo South Teaching hospital from
01st February 2014 to 30th April 2014.
Study population
All consecutive patients with non fatal acute coronary
syndrome admitted during the study period were in-
cluded. Inclusion criteria were; a) history of chest pain at
rest or other symptoms suggestive of an ACS with the
most recent episode occurring within 24 h of admission
and b) compatible ECG changes and/or positive cardiac
biomarkers.
Patients with the following features were excluded
from the study; a) Participants with an increased alcohol
intake defined as >20 g/day during the last 2 years elic-
ited in the history by the interviewer, b) Patients with
cirrhosis diagnosed prior to admission or after admission
based on the liver profile and ultrasound scan of liver, c)
Patients with known risk factors for liver disease, d) Pa-
tients who died following admission before evaluation of
NAFLD, e) use of agents known to induce fatty liver
such as steroids, chemotherapeutic agents, amiodarone
within the previous 6 months.
All patients were interviewed to obtain demographic
data and quantify the alcohol consumption.
Baseline variables
Anthropometric measures such as weight, height, body
mass index (BMI) and waist circumference were
measured. Obesity was defined as BMI ≥ 27.5 kg/m2.
High waist circumference was taken as >90 cm in males
and >80 cm in females. Fasting blood was tested for
blood glucose, total cholesterol, serum triglyceride and
LDL cholesterol. ALT level was measured. Diabetes was
defined as two FBS values >5.6 mmol/L, HbA1c > 6.5 %
or an already diagnosed case; hypertension was defined
as blood pressure > 140/90 mmHg or a previously diag-
nosed case.
Diagnosis of NAFLD
Although liver biopsy is the gold standard test to diag-
nose NAFLD, it was not performed due to the invasive
nature of the test and ethical concerns. Ultrasonography
has a sensitivity of 90 % and a specificity of 95 % when
hepatic fat infiltration detected by liver biopsy is greater
than 33 % [15]. It is a non invasive test widely adopted
for screening. Ultrasound scan of the liver was per-
formed by two experienced radiologists. Fatty liver was
diagnosed based on widely accepted criteria; increased
echogenicity of liver in comparison with the right renal
cortex, attenuation of the ultrasound beam and poor
visualization of intra hepatic structures [16]. Patient
was diagnosed to have NAFLD if both operators agreed
on the diagnosis. All the ultrasound scans were per-
formed by two experienced radiologists to minimize
inter-operator variability.
Severity of acute coronary syndrome: GRACE score
GRACE score was calculated in all patients on admis-
sion to assess severity of ACS. It takes in to account
eight independent risk factors for in-hospital death and
post-discharge death up to 6 months and is a useful pre-
dictor of outcome in ACS [17, 18]. Risk of short term
mortality ranges from 2 % in low risk categories to
>11 % in high risk groups. This categorization was used
in our study to predict mortality during hospital stay
and up to 6 months after discharge [17, 18].
Statistical analysis
Statistical analysis was performed using SPSS 17.0 ver-
sion. Continuous variables were described as mean ±
standard deviation. Number of cases and percentages
were given for categorical variables. Chi square test was
used to find the association between categorical variables
and student t-test for univariate analysis of normally dis-
tributed continuous variables and Mann Whitney U test
for variables with a skewed distribution. Intermediate
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and high risk categories according to GRACE score
were grouped together and logistic regression was
adopted to find the covariates associated with a worse
outcome in ACS. Multiple logistic regression was
used to eliminate the effect of confounding variables.
For multivariate analysis, parameters having associa-
tions with collateral development with p-values <0.10
were entered into the analysis. Statistical significance
was defined as p < 0.05.
Ethical approval
Ethical approval was obtained by the ethics review com-
mittee of University of Sri Jayewardenepura. Informed
consent was obtained from all study participants and
those who did not give consent were excluded.
Results
There were 120 participants with ACS, 75 (62.5 %) males
and 45 (37.5 %) females with an average age of 61.28 ±
11.83 years. NAFLD was identified in 56 (46.7 %).
Demographic data and metabolic risk factor profile is
depicted in Table 1.
Majority of patients (n = 117, 97.5 %) had an un-
eventful recovery while only 02 (1.7 %) patients had
persistent angina and 01 (0.8 %) underwent urgent re-
vascularization. Based on GRACE score all patients
were categorized as low-risk, intermediate risk and
high-risk according to standard criteria. GRACE score
in patients with NAFLD and without NAFLD is given
in Table 2.
Patients in high and intermediate risk of death during
the hospital stay and at 6 months were grouped to-
gether. This group was compared with the low risk
group. Logistic regression was used to identify the fac-
tors associated with an intermediate-high risk (Table 3
and Table 4). Presence of diabetes was associated with a
higher risk of in hospital death from ACS and 6 months
after discharge. This effect was not seen after correcting
for other confounding factors. Female gender was asso-
ciated with a worse outcome but did not have a signifi-
cant effect after correcting for other covariates.
Table 1 Demographic variables and metabolic risk factor profile in patients with NAFLD and without NAFLD
Variable NAFLD Non- NAFLD Total Significance
n = 56 n = 64 n = 120
Age(years) 62.9 ± 10.8 59.8 ± 12.6 61.28 ± 11.8 p = 0.157
Gender
Male 30 (53.6) 45 (70.3) 75 (62.5) p = 0.059
Female 26 (46.4) 19 (29.7) 45 (37.5)
Diabetes 38 (67.9) 32 (50.0) 70 (58.3) p = 0.048
Hypertension 44 (78.6) 40 (62.5) 84 (70.0) p = 0.055
Dyslipidaemia 29 (51.8) 21 (32.8) 50 (41.7) p = 0.035
Smoking 24 (42.9) 31 (48.4) 55 (45.8) p = 0.815
Alcohol consumption
Never 33 (58.9) 37 (57.8) 70 (58.3) p = 0.902
< 20 g/day 23 (41.1) 27 (42.2) 50 (41.7)
BMI 24.59 ± 3.5 24.69 ± 12.9 24.64 ± 9.8 p = 0.958
Obesity (BMI > 27.5 kg/m2) 12 (21.5) 03 (4.7) 15 (12.5) p = 0.005
Waist circumference 101.2 ± 13.6 101.4 ± 17.3 101.3 ± 15.6 p = 0.941
Increase waist circumference a 48 (85.7) 49 (76.6) 97 (80.8) p = 0.204
FBS 156.7 ± 72.9 134.7 ± 72.0 144.6 ± 72.9 p = 0.111
Total Cholesterol 213.6 ± 40.3 189.3 ± 26.4 200.6 ± 35.6 p < 0.001
Triglyceride 159.1 ± 46.4 122.2 ± 46.8 139.9 ± 49.9 p < 0.001
LDL-cholesterol 148.2 ± 36.2 129.5 ± 24.2 138.6 ± 31.9 p = 0.005
ALT 62.9 ± 46.2 29.4 ± 11.9 44.9 ± 36.5 p < 0.001
Type of ACS
STEMI 16 (28.6) 16 (25.0) 32 (26.7) p = 0.659
Non-STEMI 40 (71.4) 48 (75.0) 88 (73.3)
a Waist circumference >90 cm in males and >80 cm in females were considered high. Significant associations are given in bold. BMI, body mass index; FBS, fasting
blood sugar; LDL, low density lipoprotein; ALT, Alanine transaminase
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Discussion
This study evaluated the effect of NAFLD on predicted
mortality from ACS. Previous studies have compared
angiographic or multi slice CT data as a measure of cor-
onary artery disease (CAD) burden in patients with
NAFLD. Functional significance of NAFLD-related cor-
onary lesions is not proved and studies in patients with
acute coronary syndromes (ACS) are lacking [19, 20].
Furthermore, mortality data and data on South Asian
populations are sparse.
We found a NAFLD prevalence of 46.7 % among our
study participants with ACS. It is higher than the previ-
ously reported community prevalence of NAFLD in
Western countries [21] and in Sri Lanka [5]. This is an
expected finding with the accumulating evidence of a
strong association of NAFLD and CAD. In addition, our
study population represented a group with increased
metabolic risk factors compared to healthy adults. NAFLD
prevalence in our study is comparable to data from China
reporting a CT detected NAFLD prevalence of 45.8 % [6].
However, two studies conducted in western countries in-
corporating patients with ACS revealed a NAFLD preva-
lence exceeding 80 % using Ultrasonography [14, 20]. One
reason could be due to the increase prevalence of obesity
in these countries than Sri Lanka which is a known pre-
disposing factor for NAFLD. Our population had an aver-
age BMI of 24.6 and only 12.5 % were obese. More than
80 % had a higher than normal waist circumference
reflecting the higher prevalence of central obesity in Sri
Lanka. However, waist circumference was not associated
with NAFLD or with high mortality from ACS.
Diabetes, dyslipidaemia, hypertension were commoner
in the NAFLD group which is comparable to published
literature [5]. There was a non significant increase in
NAFLD among females in our study.
Our data reveal a significantly higher GRACE score in
patients with NAFLD compared to patients without
NAFLD (Table 2). More patients with NAFLD were seen
in the high and intermediate risk groups. Further ana-
lysis revealed that presence of fatty liver is independently
Table 2 GRACE score and the risk categories in patients with NAFLD and without NAFLD
ACS severity NAFLD Non-NAFLD Total Significance
n = 56 n = 64 n = 120
GRACE score
Mean ± SD
120.2 ± 26.9 92.3 ± 24.2 105.6 ± 29.0 p < 0.001
Predicted In-hospital mortality
Low risk 22 (39.3) 48 (75.0) 70 (58.3) p < 0.001
Intermediate risk 19 (33.9) 9 (14.1) 28 (23.3)
High risk 12 (21.4) 2 (3.1) 14 (11.7)
Predicted post discharge mortality at 6 months
Low risk 7 (12.5) 28 (43.8) 35 (29.2) p < 0.001
Intermediate risk 21 (37.5) 23 (35.9) 44 (36.7)
High risk 25 (44.6) 8 (12.5) 33 (27.5)
Table 3 Risk factors associated with a predicted intermediate-high risk of death from ACS during hospital stay according to GRACE
score (Multivariate logistic regression)
Variable OR (CI) Significance Adjusted OR (CI) Significance
NAFLD 6.15 (2.6–14.4) p < 0.001 31.3 (2.2–439.8) p = 0.011
Age 1.15 (1.1–1.2) p < 0.001 1.32 (1.1–1.5) p = 0.001
Female gender 8.77 (3.6–21.1) p < 0.001 2.94 (0.4–20.4) NS
Diabetes 2.36 (1.04–5.3) p = 0.039 5.85 (0.6–53.6) NS
Hypertension 3.14 (1.2–8.1) p = 0.017 1.35 (0.17–10.9) NS
Dyslipidaemia 3.43 (1.5–7.6) p = 0.003 2.16 (0.3–14.5) NS
Smoking 0.29 (0.13–0.67) p = 0.003 NS
Obesity 5.0 (1.4–17.2) p = 0.011 1.03 (0.1–10.5) NS
LDL 1.02 (1.003–1.034) p = 0.017 1.01 (0.97–1.05) NS
ALT 1.03 (1.01–1.05) p = 0.003 1.04 (0.98–1.09) NS
Waist circumference 1.01 (0.9–1.04) p = 0.374
LDL, low density lipoprotein; ALT, Alanine transaminase; NS, not significant. Significant associations are given in bold
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associated with a worse outcome. Mortality predicted by
the GRACE score during the hospital stay and post dis-
charge up to 6 months was high among NAFLD patients
with an adjusted OR of 31 and 15.6. This association
persisted after eliminating the effect of metabolic risk
factors and age. This study shows that age and NAFLD
are an important factors contributing to cardiovascular
disease related deaths. A study conducted previously re-
ported that cardiovascular death, non fatal myocardial
infarction and need for revascularization was not differ-
ent in patients with NAFLD versus patients without
NAFLD during a follow up of 87 ± 22 weeks [22]. Long
term follow up data of our cohort would also provide
useful information on the number of actual adverse car-
diac events in this group.
Important findings of note include the effect of female
gender on intermediate-high risk of mortality from ACS.
Previous studies have demonstrated that males are at
risk of severe CAD [6]. However the effect of gender on
CAD is controversial since a descriptive study found that
coronary collateral circulation was poor in females
which lost its significance when corrected for con-
founders [12]. Our results indicate that female gender
was associated with increased mortality, and this effect
was most likely due to the higher prevalence of risk
factors in females. Presence of diabetes, hypertension,
smoking, dyslipidaemia and obesity contributed to
mortality but the effect was not seen on multivariate
analysis.
Study limitations
Main limitation was that we used ultrasonography to
diagnose NAFLD . Although liver histology is the gold
standard, the invasiveness of the procedure limits its
use. Using liver histology as a standard, the positive pre-
dictive value of ultrasonography ranges from 77 to 96 %,
and the negative predictive value ranges from 65 to 87 %
[23, 24, 25]. Although our study sample was small, we
were able to give important inferences in our study.
Conclusions
Patients with NAFLD have a higher predicted mortality
from acute coronary syndrome and thus require aggres-
sive treatment of CAD. We strongly believe that it is
important to consider this novel risk factor when risk
stratifying patients with ACS.
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